Collegium Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Collegium Pharmaceutical has a total shareholder equity of $195.4M and total debt of $667.2M, which brings its debt-to-equity ratio to 341.4%. Its total assets and total liabilities are $1.1B and $947.9M respectively. Collegium Pharmaceutical's EBIT is $190.6M making its interest coverage ratio 2.8. It has cash and short-term investments of $310.5M.
Key information
341.4%
Debt to equity ratio
US$667.17m
Debt
| Interest coverage ratio | 2.8x |
| Cash | US$310.55m |
| Equity | US$195.43m |
| Total liabilities | US$947.88m |
| Total assets | US$1.14b |
Recent financial health updates
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Recent updates
Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Collegium Pharmaceutical: Thoughts After Another Strategic Move
Feb 20There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding
Feb 15We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Oct 30Sizing Up Collegium Pharmaceuticals
Oct 04Collegium Pharmaceutical: Moving Closer To The Top
Jul 12Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment
May 14Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings
May 13We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt
May 01Financial Position Analysis
Short Term Liabilities: COLL's short term assets ($537.6M) exceed its short term liabilities ($457.9M).
Long Term Liabilities: COLL's short term assets ($537.6M) exceed its long term liabilities ($490.0M).
Debt to Equity History and Analysis
Debt Level: COLL's net debt to equity ratio (182.5%) is considered high.
Reducing Debt: COLL's debt to equity ratio has increased from 12.6% to 341.4% over the past 5 years.
Debt Coverage: COLL's debt is well covered by operating cash flow (41.2%).
Interest Coverage: COLL's interest payments on its debt are not well covered by EBIT (2.8x coverage).